Evidence map›Paper›PMID 34831359›Full record

ArticleCells2021

A Unique Topoisomerase II Inhibitor with Dose-Affected Anticancer Mechanisms and Less Cardiotoxicity.

Zhi-Ying Li, Guang-Sen Xu, Xun Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Zhi-Ying LiKey Laboratory of Chemistry and Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Guang-Sen XuKey Laboratory of Chemistry and Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Xun LiInstitute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China.ORCID 0000-0002-5582-8628
Shandong University · CNMinistry of Public Security of the People's Republic of China · CN

Funding

Key Laboratory of Forensic Toxicology, Ministry of Public Security 2021FTDWFX04Natural Science Foundation of Shandong Province ZR202102230724Rolling Program of "Changjiang Scholars and Innovative Research Team in China University" IRT_17R68
6 · The paper itself

Abstract

Type II DNA topoisomerase (topo II) is an essential nuclear enzyme and a well-validated anticancer drug target. Previously, we have carried out several rounds of structural optimizations on our in-house topo II inhibitor

Indexed as

AnimalsAntineoplastic AgentsApoptosisCardiotoxicityCell Cycle CheckpointsCell Line, TumorCell ProliferationEtoposideHumansRatsTopoisomerase II InhibitorsAntineoplastic AgentsEtoposideTopoisomerase II Inhibitorsacridone derivative 6hchemotherapyDNA intercalating agentless cardiotoxicitytopo II inhibitor

Identifiers

PMID34831359
PMCPMC8621772
OpenAlexW3212894257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.